Core Viewpoint - The announcement from Huili Pharmaceutical indicates that a significant portion of shares held by the second-largest shareholder, Huang Qianyi, has been judicially frozen due to a debt contract dispute, but this will not impact the company's control or operations significantly [1][2]. Group 1: Shareholder Information - Huang Qianyi holds 27,219,439 shares, representing 6.426% of the total share capital of Huili Pharmaceutical [2]. - A total of 21,711,132 shares held by Huang have been frozen, accounting for 79.763% of his holdings and 5.125% of the company's total shares [2]. - The freezing of shares is related to a private lending dispute with Jin Zuping, who has sought property preservation through the court [2]. Group 2: Company Performance - For the first half of 2025, Huili Pharmaceutical reported revenue of approximately 453 million yuan, a decrease of 14.86% year-on-year [3]. - The net profit attributable to shareholders was approximately -80.72 million yuan, representing a decline of 223.78% year-on-year, marking the first loss in interim performance since the company went public [3]. - The basic earnings per share were reported as a loss of 0.19 yuan [3]. Group 3: Market Performance - As of September 22, the stock price of Huili Pharmaceutical closed at 24.82 yuan per share, reflecting a 1.06% increase on that day, with a total market capitalization of 10.51 billion yuan [4]. - Since the beginning of 2025, the stock price has increased by 68.39% [4].